Abstract:Background Clinical carbon ion beams offer the potential to overcome hypoxia‐induced radioresistance in pancreatic tumors, due to their high dose‐averaged Linear Energy Transfer (LETd), as previous studies have linked a minimum LETd within the tumor to improved local control. Current clinical practices at the Heidelberg Ion‐Beam Therapy Center (HIT), which use two posterior beams, do not fully exploit the LETd advantage of carbon ions, as the high LETd is primarily focused on the beams' distal edges. Different LETd‐boosting strategies, such as Spot‐scanning Hadron Arc (SHArc), could enhance LETd distribution by concentrating high‐LETd values in potential hypoxic tumor cores while sparing organs at risk. Purpose This study aims to investigate and verify different LETd‐boosting strategies using an anthropomorphic pancreas phantom. Methods Various LETd‐boosting strategies were investigated for a cylindrical and a pancreas‐shaped target in an anthropomorphic pancreas phantom. Treatment plans were optimized using single field optimization (SFO) or multi field optimization (MFO), with objective functions based on either physical dose (Phys), relative biological effectiveness (RBE)‐weighted dose, or a combination of RBE and LETd‐based objectives (LETopt). The LETd‐boosting planning strategies were optimized with the goal of increasing the minimum LETd in the tumor without compromising its homogeneous dose coverage. Beam configurations investigated included the two‐beam in‐house clinical standard (2‐SFOPhys, 2‐SFORBE and 2‐MFORBE‐LETopt), a three‐beam configuration (3‐MFORBE and 3‐MFORBE‐LETopt) and SHArc (SHArcPhys, SHArcRBE and SHArcRBE‐LETopt) using step‐and‐shoot delivery. The different plans were verified using an anthropomorphic pancreas phantom at HIT and compared to treatment planning system (TPS) predictions. Results All investigated LETd‐boosting strategies altered the LETd distribution while meeting optimization goals and constraints, resulting in varying degrees of LETd enhancement. For the cylindrical volume, the SHArc plan resulted in the highest LETd concentration in the tumor core, with the minimum LETd in the GTV scaling up to 91 keV/μm. For the pancreas‐shaped volume, however, the 3‐MFORBE‐LETopt achieved a higher minimum LETd in the GTV than SHArcRBE (75.6 and 62.3 keV/μm, respectively). When combining SHArc with LETd optimization, a minimum LETd of 76.3 keV/μm was achieved, suggesting a potential benefit from this combined approach. Most dosimetric verifications showed dose deviations to the TPS within a 5% range, for both beam‐per‐beam and total dose. LETd‐optimized and SHArc plans exhibited slightly higher mean dose deviations (2.0%—4.6%) compared to the standard RBE‐based plans (<1.5%). Conclusion This study demonstrated the feasibility of enhancing LETd in pancreatic tumors using carbon ion arc delivery coupled with LETd optimization. The possibility of delivering these plans was verified through irradiation of an anthropomorphic pancreas phantom, which showed agreement between dose measurements and predictions.

Up modulation of dose‐averaged linear energy transfer by simultaneous integrated boost in carbon‐ion radiotherapy for pancreatic carcinoma

Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy

Radiation Therapy in Locally Advanced Pancreatic Cancer with 75 Gy Simultaneous Integrated Boost: a Dosimetric Feasibility Study

Evaluating Dosimetric Constraints for Carbon Ion Radiotherapy in the Treatment of Locally Advanced Pancreatic Cancer

Investigating LETd optimization strategies in carbon ion radiotherapy for pancreatic cancer: a dosimetric study using an anthropomorphic phantom

Proton and Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer: A Phase I Dose Escalation Study.

Dose averaged linear energy transfer optimization for large sacral chordomas in carbon ion therapy

Dose-averaged linear energy transfer within the gross tumor volume of non-small-cell lung cancer affects the local control in carbon-ion radiotherapy

The Feasibility of Simultaneous Integrate Boost Technique for Locally Advanced Non-Small Cell Lung Cancer

The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET/CT guided in esophageal cancer

Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy

Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS)

A Dosimetric Analysis of Preoperative Intensity-modulated and Image-guided Radiation Therapy with and without Simultaneous Integrated Boost for Locally Advanced Rectal Cancer.

Adaptive carbon ion radiotherapy for locally advanced non‐small cell lung cancer: Organ‐sparing potential and target coverage

Failure Patterns and Outcomes of Dose Escalation of Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer: a Multicenter Cohort Study

Carbon Ion Radiotherapy Induce Metabolic Inhibition after Functional Imaging-Guided Simultaneous Integrated Boost for Prostate Cancer

Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: an Automatic Treatment Planning Study

Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer

Effectiveness of Carbon Ion Radiation in Locally Advanced Pancreatic Cancer

Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study

Intensity-modulated Proton and Carbon-Ion Radiotherapy Using a Fixed-Beam System for Locally Advanced Lung Cancer: Dosimetric Comparison with X-Ray Radiotherapy and Normal Tissue Complication Probability (NTCP) Evaluation.